Recent insights into the critical role of TME in disease progression underscored the need to investigate how metabolic reprogramming in cancer-associated fibroblasts (CAFs), adipocytes and infiltrating immune cells contributes to disease progression and resistance to ADT/AR signaling inhibitors. The gene discussed is AR; the disease is cancer.